Breast Cancer Survivorship Management

  • Phuong Khanh Morrow
Part of the MD Anderson Cancer Care Series book series (MDCCS)


Owing to improvements in screening and adjuvant therapy, survival following the diagnosis of breast cancer has improved markedly over the past three decades. This chapter will focus on MD Anderson’s recommendations for surveillance and treatment in breast cancer survivors. Because randomized trials have not demonstrated a survival benefit with intensive monitoring, current guidelines support the use of medical history review, physical examination, and annual mammograms as the bedrock of breast cancer surveillance. In addition, given the multidisciplinary approach to breast cancer treatment and surveillance, it is essential to monitor for and treat long-term effects of breast cancer treatment, including lymphedema, cardiac toxicity, ovarian failure, bone disorders, and secondary malignancies.


Breast Cancer Acute Myeloid Leukemia Breast Cancer Survivor Aromatase Inhibitor National Comprehensive Cancer Network 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

Suggested Readings

  1. Beaulac SM, McNair LA, Scott TE, et al. Lymphedema and quality of life in survivors of early-stage breast cancer. Arch Surg 2002;137:1253–1257.PubMedCrossRefGoogle Scholar
  2. Bender CM, Sereika SM, Berga SL, et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology 2006;15:422–430.PubMedCrossRefGoogle Scholar
  3. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005;353:1784–1792.PubMedCrossRefGoogle Scholar
  4. Boykoff N, Moieni M, Subramanian SK. Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response. J Cancer Surviv 2009;3:223–232.PubMedCrossRefPubMedCentralGoogle Scholar
  5. Bristow MR, Mason JW, Billingham M, et al. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J 1981;102:709–718.PubMedCrossRefGoogle Scholar
  6. Chaudary MA, Millis RR, Hoskins EO, et al. Bilateral primary breast cancer: a prospective study of disease incidence. Br J Surg 1984;71:711–714.PubMedCrossRefGoogle Scholar
  7. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087–2106.PubMedCrossRefGoogle Scholar
  8. Correa DD, Ahles TA. Neurocognitive changes in cancer survivors. Cancer J 2008;14:396–400.PubMedCrossRefGoogle Scholar
  9. Cozen W, Bernstein L, Wang F, et al. The risk of angiosarcoma following primary breast cancer. Br J Cancer 1999;81:532–536.PubMedCrossRefPubMedCentralGoogle Scholar
  10. Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010;11:1135–1141.PubMedCrossRefGoogle Scholar
  11. Early Breast Cancer Trialists’ Collaborative Group. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012;379:432–444.CrossRefGoogle Scholar
  12. Eastell R, Adams J, Clack G, et al. Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. Ann Oncol 2011;22:857–862.PubMedCrossRefGoogle Scholar
  13. Fajardo LL, Roberts CC, Hunt KR. Mammographic surveillance of breast cancer patients: should the mastectomy site be imaged? Am J Roentgenol 1993;161:953–955.CrossRefGoogle Scholar
  14. GIVIO Investigators. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. JAMA 1994;271:1587–1592.Google Scholar
  15. Goodwin PJ, Ennis M, Pritchard KI, et al. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999;17:2365–2370.PubMedGoogle Scholar
  16. Hermelink K, Kuchenhoff H, Untch M, et al. Two different sides of “chemobrain”: determinants and nondeterminants of self-perceived cognitive dysfunction in a prospective, randomized, multicenter study. Psychooncology 2010;19:1321–1328.PubMedCrossRefGoogle Scholar
  17. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042–4057.PubMedCrossRefGoogle Scholar
  18. Hojris I, Overgaard M, Christensen JJ, et al. Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Radiotherapy Committee of the Danish Breast Cancer Cooperative Group. Lancet 1999;354:1425–1430.PubMedCrossRefGoogle Scholar
  19. Hooning MJ, Aleman BM, Hauptmann M, et al. Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer. J Clin Oncol 2008;26:5561–5568.PubMedCrossRefGoogle Scholar
  20. Hurria A, Rosen C, Hudis C, et al. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J Am Geriatr Soc 2006;54:925–931.Google Scholar
  21. Jenkins V, Shilling V, Deutsch G, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 2006;94:828–834.PubMedCrossRefPubMedCentralGoogle Scholar
  22. Jones JM, Ribeiro GG. Mortality patterns over 34 years of breast cancer patients in a clinical trial of post-operative radiotherapy. Clin Radiol 1989;40:204–208.PubMedCrossRefGoogle Scholar
  23. Kaplan HG, Malmgren JA, Atwood MK. Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990–2005. BMC Cancer 2011;11:260.PubMedCrossRefPubMedCentralGoogle Scholar
  24. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer 2002;95:1592–1600.PubMedCrossRefGoogle Scholar
  25. Khan F, Amatya B, Pallant JF, et al. Factors associated with long-term functional outcomes and psychological sequelae in women after breast cancer. Breast 2012;21:314–320.PubMedCrossRefGoogle Scholar
  26. Khatcheressian JL, Wolff AC, Smith TJ, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 2006;24:5091–2097.PubMedCrossRefGoogle Scholar
  27. Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005;23:8469–8476.PubMedCrossRefGoogle Scholar
  28. Levi F, Randimbison L, Te VC, et al. Increased risk of esophageal cancer after breast cancer. Ann Oncol 2005;16:1829–1831.PubMedCrossRefGoogle Scholar
  29. Lu W, de Bock GH, Schaapveld M, et al. The value of routine physical examination in the follow up of women with a history of early breast cancer. Eur J Cancer 2011;47:676–682.PubMedCrossRefGoogle Scholar
  30. Neugut AI, Robinson E, Lee WC, et al. Lung cancer after radiation therapy for breast cancer. Cancer 1993;71:3054–3057.PubMedCrossRefGoogle Scholar
  31. Patt DA, Duan Z, Fang S, et al. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol 2007;25:3871–3876.PubMedCrossRefGoogle Scholar
  32. Pinder MC, Duan Z, Goodwin JS, et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007;25:3808–3815.PubMedCrossRefGoogle Scholar
  33. Quesnel C, Savard J, Ivers H. Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat 2009;116:113–123.PubMedCrossRefGoogle Scholar
  34. Shilling V, Jenkins V, Morris R, et al. The effects of adjuvant chemotherapy on cognition in women with breast cancer—preliminary results of an observational longitudinal study. Breast 2005;14:142–150.PubMedCrossRefGoogle Scholar
  35. Smith RE, Bryant J, DeCillis A, et al. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 2003;21:1195–1204.PubMedCrossRefGoogle Scholar
  36. Stewart A, Collins B, Mackenzie J, et al. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psychooncology 2008;17:122–130.PubMedCrossRefGoogle Scholar
  37. Tabar L, Vitak B, Chen HH, et al. Beyond randomized controlled trials: organized mammographic screening substantially reduces breast carcinoma mortality. Cancer 2001;91:1724–1731.PubMedCrossRefGoogle Scholar
  38. Tacon AM. Mindfulness: existential, loss, and grief factors in women with breast cancer. J Psychosoc Oncol 2011;29:643–656.PubMedCrossRefGoogle Scholar
  39. Wefel JS, Lenzi R, Theriault R, et al. “Chemobrain” in breast carcinoma?: a prologue. Cancer 2004a;101:466–475.PubMedCrossRefGoogle Scholar
  40. Wefel JS, Lenzi R, Theriault RL, et al. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 2004b;100:2292–2299.PubMedCrossRefGoogle Scholar
  41. Yap J, Chuba PJ, Thomas R, et al. Sarcoma as a second malignancy after treatment for breast cancer. Int J Radiat Oncol Biol Phys 2002;52:1231–1237.PubMedCrossRefGoogle Scholar

Copyright information

© The University of Texas M. D. Anderson Cancer Center 2015

Authors and Affiliations

  • Phuong Khanh Morrow
    • 1
    • 2
  1. 1.Global Development, AmgenThousand OaksUSA
  2. 2.Department of Breast Medical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations